3020 Children's Way
San Diego, CA 92123
Rady Children's Specialists of San Diego
University of London
University College - London
Hammersmith Hospital, London, University of Colorado School of Medicine
Dr. Richard Haas is a neurologist at Rady Children's Hospital-San Diego as well as director of the Mitochondrial Disease Laboratory and a professor at UC San Diego.
Dr. Haas obtained his medical degree from the University of London. He completed residencies in internal medicine, neurology and pediatrics, followed by a fellowship in pediatric neurology at the University of Colorado.
Dr. Haas specializes in mitochondrial disorders and the relationship between metabolic defects and serious neurological diseases. He and Robert Naviaux, MD, PhD, identified mutations in mitochondrial polymerase activity as the cause of Alper's syndrome, a devastating childhood mitochondrial disease. He also recently collaborated with researchers at UC Irvine to study mitochondrial dysfunction in autism.
In 1994, Dr. Haas established what is now the Mitochondrial and Metabolic Disease Center and laboratory at UC San Diego as a facility dedicated to the research and clinical evaluation of mitochondrial disorders. His attempt to merge research and patient care has been a hallmark of his career and has created a referral base of both domestic and international patients.
Dr. Haas's clinical interests include neurometabolic disease, general child neurology, Rett Syndrome, neuromuscular disease and neonatal neurology. He serves on the editorial board of the European Journal of Pediatric Neurology and is a member of the scientific advisory board of the United Mitochondrial Disease Foundation. He reviews various journals, including Proceedings of the National Academy of Sciences, Journal of Pediatric Neurology, Annals of Neurology and Molecular Genetics and Metabolism.
Dr. Haas is currently principal investigator of two clinical trials at Rady Children's. He is evaluating the safety of eteplirsen for Duchenne muscular dystrophy and, along with Drs. Mark Nespeca, Sonya Wang and Jeffrey Gold, is studying the efficacy of an intravenous drug on neonatal seizures. As director and principal investigator for the North American Mitochondrial Disease Consortium training fellowship, he aims to train clinician scientists who will be able to bring promising new treatments for mitochondrial disease into the clinical arena.
Platelet Mitochondrial Activity and Pesticide Exposure in Early Parkinson's Disease
Bronstein JM, Paul K, Yang L, Haas RH, SHults CW, Le T, Ritz B
Assessing Bioenergetic Compromise in Autism Spectrum Disorder with 31P Magnetic Resonance Spectroscopy: Preliminary Report
Golomb BA, Erickson LC, Scott-Van Zeeland AA, Koperski S, Haas RH, Wallace DC, Naviaux RK, Lincoln AJ, Reiner GE, Hamilton G
Orthostatic Tremor, Progressive External Ophthalmoplegia, and Twinkle
Milone M, Klassen BT, Landsverk ML, Haas RH, Wong LJ
Practice Patterns of Mitochondrial Disease Physicians in North America. Part 1: Diagnostic and Clinical Challenges
Parikh S, Goldstein A, Koenig MK, Scaglia F, Enns GM, Saneto R; Mitochondrial Medicine Society Clinical Directors Working Group; MMS Clinical Director's Work Group, Anselm I, Collins A, Cohen BH, DeBrosse SD, Dimmock D, Falk MJ, Ganesh J, Greene C, Gropman AL, Haas R, Kahler SG, Kamholz J, Kendall F, Korson MS, Mattman A, Milone M, Niyazov D, Pearl PL, Reimschisel T, Salvarinova-Zivkovic R, Sims K, Tarnopolsky M, Tsao CY, van Hove J, Walsh L, Wolfe LA
Automated Methods for the Analysis of Skeletal Muscle Fiber Size and Metabolic Type
Kostrominoya TY, Reiner DS, Haas RH, Ingermanson R, McDonough PM